Finally, it was striking that when studying fibrosis in the NASH microtissues the largest decreases in fibrotic endpoints were observed after treatment in the presence of TGFβ, demonstrating the value of being able to test the efficacy of a compound in varying disease states in the same model, potentially in parallel. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.